149 related articles for article (PubMed ID: 12727815)
21. Postmenopausal hormone therapy is associated with a reduced risk of colorectal cancer lacking CDKN1A expression.
Lin JH; Morikawa T; Chan AT; Kuchiba A; Shima K; Nosho K; Kirkner G; Zhang SM; Manson JE; Giovannucci E; Fuchs CS; Ogino S
Cancer Res; 2012 Jun; 72(12):3020-8. PubMed ID: 22511578
[TBL] [Abstract][Full Text] [Related]
22. Association between polymorphisms in cell cycle genes and advanced prostate carcinoma.
Kibel AS; Jin CH; Klim A; Luly J; A Roehl K; Wu WS; Suarez BK
Prostate; 2008 Aug; 68(11):1179-86. PubMed ID: 18459109
[TBL] [Abstract][Full Text] [Related]
23. The role of p21 3'UTR gene polymorphism in the risk of prostate cancer: a pilot study.
Sivoňová MK; Vilčková M; Jurečeková J; Hatok J; Dobrota D; Dušenka R; Kliment J
Mol Med Rep; 2013 Mar; 7(3):986-90. PubMed ID: 23292332
[TBL] [Abstract][Full Text] [Related]
24. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse.
Di Cristofano A; De Acetis M; Koff A; Cordon-Cardo C; Pandolfi PP
Nat Genet; 2001 Feb; 27(2):222-4. PubMed ID: 11175795
[TBL] [Abstract][Full Text] [Related]
25. Deficiency of CDKN1A or both CDKN1A and CDKN1B affects the pubertal development of mouse Leydig cells.
Lin H; Huang Y; Su Z; Zhu Q; Ge Y; Wang G; Wang CQ; Mukai M; Holsberger DR; Cooke PS; Lian QQ; Ge RS
Biol Reprod; 2015 Mar; 92(3):77. PubMed ID: 25609837
[TBL] [Abstract][Full Text] [Related]
26. Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene.
Facher EA; Becich MJ; Deka A; Law JC
Cancer; 1997 Jun; 79(12):2424-9. PubMed ID: 9191533
[TBL] [Abstract][Full Text] [Related]
27. Role of the CDKN1A/p21, CDKN1C/p57, and CDKN2A/p16 genes in the risk of atherosclerosis and myocardial infarction.
Rodríguez I; Coto E; Reguero JR; González P; Andrés V; Lozano I; Martín M; Alvarez V; Morís C
Cell Cycle; 2007 Mar; 6(5):620-5. PubMed ID: 17351341
[TBL] [Abstract][Full Text] [Related]
28. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor.
Ingles SA; Ross RK; Yu MC; Irvine RA; La Pera G; Haile RW; Coetzee GA
J Natl Cancer Inst; 1997 Jan; 89(2):166-70. PubMed ID: 8998186
[TBL] [Abstract][Full Text] [Related]
29. Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population.
Driver KE; Song H; Lesueur F; Ahmed S; Barbosa-Morais NL; Tyrer JP; Ponder BA; Easton DF; Pharoah PD; Dunning AM;
Carcinogenesis; 2008 Feb; 29(2):333-41. PubMed ID: 18174243
[TBL] [Abstract][Full Text] [Related]
30. Allelic variant at -79 (C>T) in CDKN1B (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels.
Landa I; Montero-Conde C; Malanga D; De Gisi S; Pita G; Leandro-García LJ; Inglada-Pérez L; Letón R; De Marco C; Rodríguez-Antona C; Viglietto G; Robledo M
Endocr Relat Cancer; 2010 Jun; 17(2):317-28. PubMed ID: 20075119
[TBL] [Abstract][Full Text] [Related]
31. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer.
Huang SP; Wu WJ; Chang WS; Wu MT; Chen YY; Chen YJ; Yu CC; Wu TT; Lee YH; Huang JK; Huang CH
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2217-24. PubMed ID: 15598783
[TBL] [Abstract][Full Text] [Related]
32. CDKN1B V109G polymorphism frequency and prostate cancer risk in Taiwan.
Huang SP; Yu CC; Liu CC; Wu TT; Huang CH; Wu MT
Urol Int; 2008; 81(1):36-40. PubMed ID: 18645269
[TBL] [Abstract][Full Text] [Related]
33. Association of p53 and CDKN1A genotypes with endometriosis.
Ying TH; Tseng CJ; Tsai SJ; Hsieh SC; Lee HZ; Hsieh YH; Bau DT
Anticancer Res; 2011 Dec; 31(12):4301-6. PubMed ID: 22199295
[TBL] [Abstract][Full Text] [Related]
34. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
[TBL] [Abstract][Full Text] [Related]
35. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models.
Jackson RJ; Adnane J; Coppola D; Cantor A; Sebti SM; Pledger WJ
Oncogene; 2002 Dec; 21(55):8486-97. PubMed ID: 12466968
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer: simplicity to complexity.
Peters ME; Ostrander EA
Nat Genet; 2001 Feb; 27(2):134-5. PubMed ID: 11175773
[TBL] [Abstract][Full Text] [Related]
37. Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma.
Kibel AS; Ahn J; Isikbay M; Klim A; Wu WS; Hayes RB; Isaacs WB; Daw EW
Prostate; 2016 Apr; 76(5):479-90. PubMed ID: 26708993
[TBL] [Abstract][Full Text] [Related]
38. Tbx2 controls lung growth by direct repression of the cell cycle inhibitor genes Cdkn1a and Cdkn1b.
Lüdtke TH; Farin HF; Rudat C; Schuster-Gossler K; Petry M; Barnett P; Christoffels VM; Kispert A
PLoS Genet; 2013; 9(1):e1003189. PubMed ID: 23341776
[TBL] [Abstract][Full Text] [Related]
39. Genetic polymorphisms in CDH1 and Exo1 genes elevate the prostate cancer risk in Bangladeshi population.
Imtiaz H; Afroz S; Hossain MA; Bellah SF; Rahman MM; Kadir MS; Sultana R; Mazid MA; Rahman MM
Tumour Biol; 2019 Mar; 41(3):1010428319830837. PubMed ID: 30880589
[TBL] [Abstract][Full Text] [Related]
40. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer.
Roh JW; Kim JW; Park NH; Song YS; Park IA; Park SY; Kang SB; Lee HP
Gynecol Oncol; 2004 May; 93(2):499-505. PubMed ID: 15099969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
